The NeoTrio trial (ClinicalTrials.gov registration: NCT02858921) was designed to determine whether targeted therapy (dabrafenib plus trametinib) enhances the benefit of neoadjuvant anti-PD-1 (pembrolizumab) in stage III resectable BRAF-mutant melanoma. This evidence concerns the gene BRAF and melanoma.